deep margin

New episodes with @HeadNeckMD and @DrChrisNutting please check them out some important topics and more to come! @nearlobey open.spotify.com/show/1ijtfPVsb…

Pleased as punch to be invited onto the Deep Margin podcast, now a fixture in HN calendar. Privilege to follow @DavidSherMD @DrUppaluri Great fun chatting salvage surgery with @nearlobey @will_oncology Serious topic, yet an easy listen. Do tune in tinyurl.com/57s3jynv

I don't think I've ever had this much fun talking about radiotherapy. We discussed ENI, immunotherapy (and radiotherapy) in metastatic and non-metastatic HNSCC, oligometastatic disease, to name a few.

New episode alert with the wonderful @DavidSherMD who talks us through the immunotherapy radiation paradigm…. open.spotify.com/episode/11HpoI…

#ESMOAsia25 🚨JUPITER-02 Final 6-year OS analysis presented! 1L toripalimab + gem/cis in pts with RM-Nasopharyngeal Ca Median OS 64.8 vs 33.7 mo (HR 0.62; p<0.01) Adjusted post-prog IO: 61.0 vs 25.1 mo (HR O.52) Confirms long-term toriGP combo efficacy 👇Updated situation of 1L NPC @OncoAlert @brunolarvol #oncoalertAF #NPC #Immunotherapy

Had a lot of fun discussing perioperative trials in LA-HNSCC with @deepmargin_pod @will_oncology BenO'Leary !!! KEYNOTE-689, NIVOPOSTOP and future directions! @DrHaddadRobert @imrtlee @HeadNeckMD open.spotify.com/episode/5s0XnZ… At end we discuss @jvuppaluri favorite @premierleague team!

new episodes out Kevin Harrington on ESMO and Ravi Uppaluri on KN689/NIVOPOSTOP - spread the word! @DrUppaluri @PaulJiL @AriRosenbergMD @h_mehanna @HeadNeckMD

Meeting ID: 370 675 051 005 95 Passcode: yN62wT34 Please now join this webinar via Teams with details above.

Right we have arrived! Some absolutely great info in our first episode with the wonderful @AriRosenbergMD open.spotify.com/episode/7yKBJ0…

"A Simplified Guide to the Immune System." pin.it/1Krc811Dg

@VinPaleri @HeadNeckMD

Episode 1 with the absolute legend @AriRosenbergMD discussing ADC data, nightclubs and military strategy open.spotify.com/episode/7yKBJ0…

#ESMO25 @myESMO Abstracts are now released! Here is my summary with preliminary results from the best communications for: 🔸Head&Neck SCC - Early disease - Advanced disease 🔸Nasopharyngeal Carcinoma 🔸SalivaryGlandCancer & Sinonasal @oncodaily @OncoAlert @brunolarvol @OncBrothers @FundacionTTCC #headneckcancer #ESMO2025

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors

FDA approves adjuvant cemiplimab for high risk cutaneous SCC based on C-POST phase III trial presented at #ASCO2025 #skincancer @OncoAlert @brunolarvol @myESMO #CSCC 350mgQ3Wx4cycles followed by 700mgQ6Wx6cycles High-risk disease criteria: 🔸Nodal: ECE + ≥1 node ≥20 mm or ≥3 involved nodes. 🔸 Non-nodal: in-transit mets, p/n of named nerves, T4 bone invasion, or local recurrence with extra adverse features (e.g. ≥N2b, T3 > 4 cm, or poor differentiation ≥ 20 mm)

2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance A stunningly preserved evolutionary regulation that erases or controls self-reactive T cells

🚨Update in Head&Neck SCC @NCCN Evidence Blocks 💉neoadjuvant #pembrolizumab added! Highlighting indication for resectable stage III/IVa CPS+, excluding N3 💉Sc R/M #nivolumab (review new doses 600mgQ2W/1200mgQ4W) 👇v5 Pics @OncoAlert @brunolarvol @BAHNOOfficial @ttccgroup